Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $4.41 and traded as high as $4.43. Treace Medical Concepts shares last traded at $4.42, with a volume of 157,213 shares traded.
Analyst Upgrades and Downgrades
Several brokerages recently commented on TMCI. Weiss Ratings upgraded Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Truist Financial lifted their target price on Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a report on Monday, August 10th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $5.17.
Check Out Our Latest Analysis on Treace Medical Concepts
Treace Medical Concepts Stock Performance
Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. The firm had revenue of $45.38 million during the quarter, compared to analyst estimates of $44.02 million. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. As a group, equities analysts predict that Treace Medical Concepts, Inc. will post -0.83 EPS for the current fiscal year.
Insider Activity at Treace Medical Concepts
In other Treace Medical Concepts news, CEO John Treace bought 39,944 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was purchased at an average price of $4.44 per share, for a total transaction of $177,351.36. Following the completion of the transaction, the chief executive officer directly owned 7,388,383 shares of the company’s stock, valued at $32,804,420.52. This trade represents a 0.54% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders acquired 55,944 shares of company stock worth $246,841. 23.42% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE bought a new stake in Treace Medical Concepts during the second quarter worth about $13,154,000. BlackRock Inc. bought a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $5,492,000. Weber Capital Management LLC ADV bought a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $2,346,676. Renaissance Technologies LLC purchased a new position in shares of Treace Medical Concepts during the 1st quarter valued at about $701,000. Finally, Ieq Capital LLC purchased a new position in shares of Treace Medical Concepts during the 2nd quarter valued at about $437,000. Institutional investors own 84.08% of the company’s stock.
About Treace Medical Concepts
Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company’s technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.
Treace’s primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.
Featured Stories
- Five stocks we like better than Treace Medical Concepts
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
